Solid U.S. growth and moderate inflation should support credit markets in 2025, creating a stable environment for high yield bonds and leveraged loans. Historically elevated yield levels are likely to ...

The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

Guggenheim has expanded its risk-management ... After holding large weights in corporates and bank loans in its early years, that stake had ‎shrunk to 5.1% of ‎assets at Dec. 31, 2019 ...

Barclays announces the appointments of Isobel van Daesdonk and Scott Willard as Managing Directors within the Financial Sponsors Group. Ms. van Daesdonk and Mr. Willard will be based in New York, and ...

DAVOS, Switzerland (Reuters) - Guggenheim Partners' chief investment officer forecast on Monday that the U.S. Federal Reserve is likely to cut interest rates roughly every quarter in 2025 ...

Guggenheim adjusted its outlook for New York Times Company (NYSE:NYT), reducing the price target from $55.00 to $52.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, ...

Consult a professional regarding your specific legal or tax matters. Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ...

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...

Guggenheim analyst Robert Drbul maintained a Buy rating on Tapestry (TPR – Research Report) yesterday and set a price target of $90.00. The ...